Prospective study of prevention of recurrence of prostate cancer with bone metastasis and prevention of bone mineral density decrease by combination therapy with hormonal therapy and zoledronic acid
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000001137
- Lead Sponsor
- Kanazawa University, Department of Urology
- Brief Summary
Zoledronic acid improved PSA-PFS in PCa patients with GS 8 and more 8 when Zoledronic acid was administarated from initial hormonal treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Not provided
1) The person whom we gave bisphosphonate before beginning of dosage 2)The person who performed bone radiotherapy within beginning of dosage three months 3)serum correction Ca value less than 8.0 mg or active cancer except equal or more than 11.6 mg 4)serum creatinine:more than 3.0mg / dL 5) Active cancer except prostate cancer is the patient in less than 3 years 6)The patient having a grave complication 7)In addition, the patient whom we intended for it, and it was judged judgment of a doctor to be inadequate 8)The case that does not fall under criteria for selection of nine case) subject cases with a plan to perform invasive dentist treatment 9)Bisphosphonate, it is a case with anaphylactic medical history
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method recurrence free survival, survival time, survival rate
- Secondary Outcome Measures
Name Time Method bone mineral density